摘要The"Global Cancer Statistics Report 2022"estimates that there were approximately 20 million new cancer cases world-wide,including 9.7 million in females,of which 2.31 million were breast cancer cases1.Breast cancer is the most common malignant tumor in women and one of the leading causes of cancer-related deaths.Breast cancer treatment primar-ily involves surgery,often in combination with chemother-apy,radiotherapy,endocrine therapy,and targeted therapies.Despite continuous advances in these treatments,significant limitations remain.Traditional chemotherapy and radiother-apy are effective but lack specificity.While endocrine and human epidermal growth factor receptor 2(HER2)targeted therapies are highly effective in some breast cancer subtypes,targeted therapies offer limited benefit to patients with tri-ple-negative breast cancer(TNBC).However,antibody-drug conjugates(ADCs)have shown great promise in overcoming these challenges.